Rapid Generation of Human Therapuetic Antibodies Against Influenza

快速产生人类流感治疗抗体

基本信息

批准号：
7480790
负责人：
YOSEF REFAELI
金额：
$ 18.07万
依托单位：
TAIGA BIOTECHNOLOGIES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-08-15 至 2010-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7480790
关键词：
Adult Antibodies Antibody Formation Antibody Specificity Antibody-Producing Cells Antigenic Specificity Antigens Autoantibodies Autoantigens B Cell Proliferation B-Lymphocytes Binding Biological Biological Process Bone Marrow Stem Cell Cell Line Cell Lineage Cells Chimeric Proteins Clinic Consensus Sequence DNA Face Future Generations Glycoproteins Goals H5 hemagglutinin HIV-1 Health Hemagglutinin Hematopoietic stem cells Human Immune Immune Complex Diseases Immune response Immunization Individual Infection prevention Influenza Influenza A Virus, H1N1 Subtype Influenza A Virus, H5N1 Subtype Influenza A virus Kidney Lymphoma Malaria Membrane Proteins Methods Monoclonal Antibodies Mus Neuraminidase Numbers Passive Immunization Personal Satisfaction Persons Phase Phenotype Principal Investigator Process Production Protein Overexpression Public Health Receptors, Antigen, B-Cell Role Science Signal Transduction Specificity Staging System T-Lymphocyte Technology Testing Therapeutic Therapeutic Agents Therapeutic Intervention Therapeutic antibodies Time Transduction Gene Transgenic Mice Transgenic Organisms Tuberculosis Umbilical Cord Blood Vaccines Viral Virus Virus Diseases aged anti-influenza clinical application cytokine human adult stem cell human monoclonal antibodies influenzavirus mouse model neutralizing antibody novel novel strategies pandemic disease pandemic influenza programs research study response vaccination strategy

项目摘要

DESCRIPTION (provided by applicant): Using a method of retroviral gene transduction we have been able to generate conditionally immortalized long-term hematopoietic stem cell lines from mouse bone marrow stem cells, fetal cord blood and adult bone marrow stem cells. Phase I of this project includes testing existing mouse antibodies against Influenza for their ability to neutralize pathogenic strains of Influenza and adapting this technology to generate human antibodies against Influenza in a mouse model using human adult stem cells. Phase II of the project will involve optimizing large-scale production and testing of human anti-influenza antibodies. PUBLIC HEALTH RELEVANCE: This project seeks to optimize a novel method to rapidly generate human therapeutic antibodies against the Influenza virus in a mouse model using human adult stem cell lines. Once this method has been validated for Influenza, the long-term goal to benefit public health will be to use this system to generate antibodies for clinical applications in a variety of global health issues including, but not limited to, HIV-1, tuberculosis and malaria.

描述（由申请人提供）：使用逆转录病毒基因转导方法，我们能够从小鼠骨髓干细胞，胎儿血液和成年骨髓干细胞中产生有条件永生的长期造血干细胞。该项目的第一阶段包括测试针对流感的现有小鼠抗体，其能够中和流感的致病性菌株并适应该技术以使用人类成人干细胞在小鼠模型中生成对流感的人类抗体。该项目的第二阶段将涉及优化人类抗Influenza抗体的大规模生产和测试。公共卫生相关性：该项目旨在优化一种新方法，以使用人类成人干细胞系在小鼠模型中快速生成针对流感病毒的人类治疗抗体。一旦对流感验证了这种方法，将使公共卫生的长期目标是利用该系统在各种全球健康问题中为临床应用生成抗体，包括但不限于HIV-1，结核病，结核病和疟疾。